Compare iShares MSCI South Korea ETF (EWY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI South Korea ETF trades at $171.68, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWY | RXRX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $6.79 |
52-Week Low | $71.22 | $2.84 |
Market Cap | — | $1.78B |
Enterprise Value | — | $1.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) trades at $166.09, up 1.2% with a neutral technical signal. The ETF faces volatility from South Korea's AI and semiconductor exposure, with recent news highlighting both government support initiatives and significant market swings. Technical indicators show mixed signals with RSI at 75.01 suggesting overbought conditions while moving averages remain bullish.
The outlook remains cautious as South Korean equities navigate AI-driven volatility and regulatory changes. Goldman Sachs maintains strong conviction with 90% upside potential for Korean stocks, but recent ETF speculation curbs and semiconductor stock declines present near-term headwinds for EWY investors.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
